-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O0bKBAqn1gsHkXI5zGHGoxYkQeQ+r6gaG5YiWcpbQ/Q3F0PRM0vkHwKHyx+VqBOD dT/9pnPQhaJUJ7vosn8z+Q== 0001104659-11-003357.txt : 20110127 0001104659-11-003357.hdr.sgml : 20110127 20110127130130 ACCESSION NUMBER: 0001104659-11-003357 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20110127 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110127 DATE AS OF CHANGE: 20110127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRACEUTICAL INTERNATIONAL CORP CENTRAL INDEX KEY: 0001050007 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 870515089 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23731 FILM NUMBER: 11551424 BUSINESS ADDRESS: STREET 1: 1400 KEARNS BOULEVARD STREET 2: 2ND FLOOR CITY: PARK CITY STATE: UT ZIP: 84060 BUSINESS PHONE: 4356556000 MAIL ADDRESS: STREET 1: 1400 KEARNS BOULEVARD STREET 2: 2ND FLOOR CITY: PARK CITY STATE: UT ZIP: 84060 8-K 1 a11-4335_28k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 27, 2011

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

(State of incorporation)

 

000-23731

(Commission
File Number)

 

87-0515089

(IRS Employer
Identification No.)

 

1400 Kearns Boulevard, 2nd Floor

Park City, Utah
(Address of principal executive offices)

 

84060
(Zip Code)

 

Registrant’s telephone number, including area code: (435) 655-6106

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On January 27, 2011, Nutraceutical International Corporation reported results for the fiscal 2011 first quarter ended December 31, 2010.  The press release reporting the results is attached to this Form 8-K as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibits.

 

99.1                           Press release issued by Nutraceutical dated January 27, 2011.

 

This Form 8-K and the attached Exhibit are furnished to comply with Item 2.02 and Item 9.01 of Form 8-K.  Neither this Form 8-K nor the attached Exhibit are to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall this Form 8-K nor the attached Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933 (except as shall be expressly set forth by specific reference in such filing).

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

(Registrant)

 

 

 

 

Date: January 27, 2011

By:

/s/ Cory J. McQueen

 

 

Cory J. McQueen

 

 

Vice President and Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

2



 

EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

99.1

 

Press release issued by Nutraceutical dated January 27, 2011.

 

3


EX-99.1 2 a11-4335_2ex99d1.htm EX-99.1

Exhibit 99.1

 

FOR:

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

 

 

CONTACT:

 

Cory J. McQueen

 

 

Vice President and

 

 

Chief Financial Officer

 

 

(435) 655-6106

 

NUTRACEUTICAL REPORTS FISCAL 2011 Q1 RESULTS

 

PARK CITY, Utah, Jan 27/PRNewswire-First Call/—Nutraceutical International Corporation (NASDAQ:  NUTR) today reported results for the fiscal 2011 first quarter ended December 31, 2010.  Net sales for the fiscal 2011 first quarter were $45.2 million compared to $44.8 million for the same quarter of fiscal 2010.  For the first quarter of fiscal 2011, net income was $3.9 million, or $0.38 diluted earnings per share, compared to net income of $3.9 million, or $0.37 diluted earnings per share, for the same quarter of fiscal 2010.

 

Operating cash flow for the fiscal 2011 first quarter ended December 31, 2010 was $6.3 million compared to $6.0 million for the same period of fiscal 2010.  This operating cash flow, combined with net borrowings of $2.0 million, was primarily used to invest $7.1 million in acquisitions of branded natural product businesses and $1.5 million in purchases of property and equipment.

 

Bill Gay, chairman and chief executive officer, commented, “Our fiscal 2011 first quarter net sales, net income and EBITDA remained strong.   At the same time, the health and natural foods retail market remains very competitive.  It appears to us that during this quarter many retailers — both large and small — continued to struggle with mixed operating success as a result of the marginal economic environment.”

 

Mr. Gay continued, “We completed two small acquisitions in the first quarter. One of the acquisitions, which was acquired through a bankruptcy sale, provided us with a facility and liquid manufacturing capabilities.  This facility also provided a platform for us to begin consolidation of many of our existing liquid products as well as products acquired as part of the second acquisition.  Our focus remains on identifying small to medium size companies that primarily provide new product offerings not currently found in our current product portfolio.   In addition, we will continue to refine and improve our sales and marketing programs in an effort to further strengthen them.  We look forward to another successful and solid financial year.”

 

ABOUT NUTRACEUTICAL

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores.  Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.  Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded

 



 

nutritional supplements.  We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

 

We manufacture and sell nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Nature’s Life®, LifeTime®, Natural Balance®, bioAllers®, Herbs for Kids™, NaturalCare®, Health from the Sun®, Life-flo®, Organix South®, Pioneer® and Monarch Nutraceuticals™.

 

We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom’s Natural Foods™ and Cornucopia Community Market™.  We also own health food stores, which operate under the trade names Fresh Vitamins™ and Granola’s™.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 5,500 SKUs, including over 700 SKUs sold internationally.  We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as “believe,” “expects,” “plan,” “intend,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cau se industry trends or our actual results to be materially different from any future results expressed or implied by these statements.  Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types,  (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.  Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC’s websit e (www.sec.gov).

 

© 2011 Nutraceutical Corporation.  All rights reserved.

 

# # #

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

 

 

 

December 31,

 

September 30,

 

 

 

2010

 

2010

 

Assets

 

 

 

 

 

Current assets, net

 

$

58,464

 

$

58,294

 

Property, plant and equipment, net

 

65,992

 

61,733

 

Goodwill

 

6,001

 

5,338

 

Other non-current assets, net

 

32,019

 

30,966

 

 

 

$

162,476

 

$

156,331

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

$

17,276

 

$

45,673

 

Long-term liabilities

 

31,619

 

1,739

 

Stockholders’ equity

 

113,581

 

108,919

 

 

 

$

162,476

 

$

156,331

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

 

 

 

Three months ended December 31,

 

 

 

2010

 

2009

 

Net sales

 

$

45,243

 

$

44,839

 

Cost of sales

 

21,781

 

21,365

 

Gross profit

 

23,462

 

23,474

 

Operating expenses

 

 

 

 

 

Selling, general and administrative

 

16,735

 

16,749

 

Amortization of intangible assets

 

390

 

298

 

Income from operations

 

6,337

 

6,427

 

Interest and other (income) expense, net

 

171

 

109

 

Income before provision for income taxes

 

6,166

 

6,318

 

Provision for income taxes

 

2,219

 

2,374

 

 

 

 

 

 

 

Net income

 

$

3,947

 

$

3,944

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

Basic

 

$

0.38

 

$

0.38

 

Diluted

 

0.38

 

0.37

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

Basic

 

10,378,513

 

10,487,640

 

Diluted

 

10,462,089

 

10,569,411

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

EBITDA SCHEDULE

(unaudited; dollars in thousands)

 

 

 

Three months ended December 31,

 

 

 

2010

 

2009

 

 

 

 

 

 

 

Net income

 

$

3,947

 

$

3,944

 

Provision for income taxes

 

2,219

 

2,374

 

Interest and other (income) expense, net (1)

 

171

 

109

 

Depreciation and amortization

 

1,942

 

1,760

 

 

 

 

 

 

 

EBITDA

 

$

8,279

 

$

8,187

 

 


(1)         Includes amortization of deferred financing fees.

 

Non-GAAP Financial Measures

 

EBITDA (a non-GAAP measure) is defined in our debt covenants and performance measures as earnings before net interest and other (income) expense, taxes, depreciation and amortization.  We believe that EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance.  EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation.  Furthermore, EBITDA is not intended to be a substitute for cash flows from operating activities, as a measure of liquidity, or an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.

 


-----END PRIVACY-ENHANCED MESSAGE-----